Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian population

Vaccine

Volumn 30, Issue 30, 2012, Pages 4552-4557

  Phua, Kong Boo ^a   Lim, Fong Seng ^b   Lau, Yu Lung ^c   Nelson, Edmund Anthony Severn ^d   Huang, Li Min ^e   Quak, Seng Hock ^f   Lee, Bee Wah ^g   Doorn, Leen Jan van ^h   Teoh, Yee Leong ^b,i   Tang, Haiwen ⁱ   Suryakiran, P V ⁱ   Smolenov, Igor V ⁱ   Bock, Hans L ⁱ   Han, Htay Htay ⁱ  

^a KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^b NATIONAL HEALTHCARE GROUP POLYCLINICS   (Singapore)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^g MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

^h Delft Diagnostic Laboratory   (Netherlands)

ⁱ GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

3years; Efficacy; Gastroenteritis; RIX4414; Rotavirus

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EVALUATION AND FOLLOW UP; GASTROENTERITIS; HONG KONG; HUMAN; IMMUNIZATION; INFANT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGAPORE; TAIWAN; UNSPECIFIED SIDE EFFECT; URBAN POPULATION; VIRUS STRAIN;

ASIAN CONTINENTAL ANCESTRY GROUP; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; GASTROENTERITIS; HONG KONG; HUMANS; INFANT; MALE; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SINGAPORE; TAIWAN; VACCINES, ATTENUATED;

EID: 84862020627     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.030     Document Type: Article

References (36)

1. Parashar U.D., Hummelman E.G., Bresee J.S., Miller M.A., Glass R.I. Global illness and deaths caused by rotavirus disease in children. Emerging Infectious Diseases 2003, 9:565-572.
2. Parashar U.D., Burton A., Lanata C., Boschi-Pinto C., Shibuya K., Steele D., et al. Global mortality associated with rotavirus disease among children in 2004. Journal of Infectious Diseases 2009, 200(Suppl. 1):S9-S15.
3. Glass R.I., Parashar U.D., Bresee J.S., Turcios R., Fischer T.K., Widdowson M.A., et al. Rotavirus vaccines current prospects and future challenges. Lancet 2006, 368:323-332.
4. World Health Organization Rotavirus vaccines. Weekly Epidemiological Record 2007, 82:285-295.
5. Bresee J.S., Hummelman E., Nelson E.A., Glass R.I. Rotavirus in Asia: the value of surveillance for informing decisions about the introduction of new vaccines. Journal of Infectious Diseases 2005, 192(Suppl. 1):S1-S5.
6. Nelson E.A., Tam J.S., Bresee J.S., Poon K.H., Ng C.H., Ip K.S., et al. Estimates of rotavirus disease burden in Hong Kong: hospital-based surveillance. Journal of Infectious Diseases 2005, 192(Suppl. 1):S71-S79.
7. Grimwood K., Lambert S.B. Rotavirus vaccines: opportunities and challenges. Human Vaccines 2009, 5:57-69.
8. Santos N., Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Reviews in Medical Virology 2005, 15:29-56.
9. Centers For Disease Control And Prevention (Cdc) Rotavirus surveillance - worldwide, 2001-2008. MMWR Morbidity and Mortality Weekly Report 2008, 57:1255-1257.
10. Murphy T.V., Gargiullo P.M., Massoudi M.S., Nelson D.B., Jumaan A.O., Okoro C.A., et al. Intussusception among infants given an oral rotavirus vaccine. New England Journal of Medicine 2001, 344:564-572.
11. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine 2006, 354:11-22.
12. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (Wc3) reassortant rotavirus vaccine. New England Journal of Medicine 2006, 354:23-33.
13. Vesikari T., Karvonen A., Prymula R., Schuster V., Tejedor J.C., Cohen R., et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2years of life in European infants: randomised, double-blind controlled study. Lancet 2007, 370:1757-1763.
14. Block S.L., Vesikari T., Goveia M.G., Rivers S.B., Adeyi B.A., Dallas M.J., et al. Efficacy, Immunogenicity, and safety of a pentavalent human-bovine (Wc3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics 2007, 119:11-18.
15. Linhares A.C., Velazquez F.R., Perez-Schael I., Saez-Llorens X., Abate H., Espinoza F., et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008, 371:1181-1189.
16. Chang C.C., Chang M.H., Lin T.Y., Lee H.C., Hsieh W.S., Lee P.I. Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants In Taiwan. Journal of the Formosan Medical Association 2009, 108:280-285.
17. Phua K.B., Lim F.S., Lau Y.L., Nelson E.A., Huang L.M., Quak S.H., et al. Safety and efficacy of human rotavirus vaccine during the first 2years of life in Asian infants: randomised, double-blind, controlled study. Vaccine 2009, 27:5936-5941.
18. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhoea in African infants. New England Journal of Medicine 2010, 362:289-298.
19. Zaman K., Dang D.A., Victor J.C., Shin S., Yunus M., Dallas M.J., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:615-623.
20. Armah G.E., Sow S.O., Breiman R.F., Dallas M.J., Tapia M.D., Feikin D.R., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:606-614.
21. Nelson E.A., Glass R.I. Rotavirus realising the potential of a promising vaccine. Lancet 2010, 376:568-570.
22. World Health Organization Meeting of the immunization strategic advisory group of experts, April 2009 - conclusions and recommendations. Weekly Epidemiological Record 2009, 84:220-236.
23. Salinas B., Perez Schael I., Linhares A.C., Ruiz Palacios G.M., Guerrero M.L., Yarzabal J.P., et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, Rix4414: a randomized, placebo-controlled trial in Latin American infants. Pediatric Infectious Disease Journal 2005, 24:807-816.
24. Cheuvart B., Friedland L.R., Abu-Elyazeed R., Han H.H., Guerra Y., Verstraeten T. The human rotavirus vaccine Rix4414 in infants: a review of safety and tolerability. Pediatric Infectious Disease Journal 2009, 28:225-232.
25. Ruuska T., Vesikari T. Rotavirus disease in finish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scandinavian Journal of Infectious Diseases 1990, 22:259-267.
26. Van Doorn L.J., Kleter B., Hoefnagel E., Stainier I., Poliszczak A., Colau B., et al. Detection and genotyping of human rotavirus Vp4 And Vp7 genes by reverse transcriptase PCR and reverse hybridization. Journal of Clinical Microbiology 2009, 47:2704-2712.
27. Newburger J.W., Takahashi M., Gerber M.A., Gewitz M.H., Tani L.Y., Burns J.C., et al. Diagnosis, treatment, and long-term management of kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004, 110:2747-2771.
28. Nelson E.A., Bresee J.S., Parashar U.D., Widdowson M.A., Glass R.I. Rotavirus epidemiology the Asian rotavirus surveillance network. Vaccine 2008, 26:3192-3196.
29. De Vos B., Han H.H., Bouckenooghe A., Debrus S., Gillard P., Ward R., et al. Live attenuated human rotavirus vaccine, Rix4414, provides clinical protection in infants against rotavirus strains with and without shared g and p genotypes: integrated analysis of randomized controlled trials. Pediatric Infectious Disease Journal 2009, 28:261-266.
30. Franco M.A., Angel J., Greenberg H.B. Immunity and correlates of protection for rotavirus vaccines. Vaccine 2006, 24:2718-2731.
31. Vesikari T., Karvonen A., Prymula R., Schuster V., Tejedor J.C., Thollot F., et al. Immunogenicity and safety of the human rotavirus vaccine rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine 2010, 28:5272-5279.
32. Gsk Biologicals. Study No. 444563-023 (Rota-023). Efficacy data from visit 1 to visit 4 [updated 05.06.09; accessed 09.05.11].
33. Zaman K., Sack Da, Yunus M., Arifeen Se, Podder G., Azim T., et al. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16weeks of age. Vaccine 2009, 27:1333-1339.
34. Phua K.B., Quak S.H., Lee B.W., Emmanuel S.C., Goh P., Han H.H., et al. Evaluation of Rix4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. Journal of Infectious Diseases 2005, 192(Suppl. 1):S6-S16.
35. Tan N., Teoh Yl, Phua Kb, Quak Sh, Lee Bw, Teo Hj, et al. An update of paediatric intussusception incidence in Singapore: 1997-2007, 11years of intussusception surveillance. Annals of the Academy of Medicine Singapore 2009, 38:690-692.
36. Hong Kong Intussusception Study Group Intussusception trends in Hong Kong children. Hong Kong Medical Journal 2007, 13:279-283.